Gliom nồng độ thấp kiểu hoang dã IDH với các đặc điểm phân tử của glioblastoma: một tổng quan hệ thống và phân tích tổng hợp

Adachi JI, Shirahata M, Suzuki T et al (2021) Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma. Brain Tumor Pathol 38:201–209 Aibaidula A, Chan AK, Shi Z et al (2017) Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 19:1327–1337 Akyerli CB, Yuksel S, Can O et al (2018) Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. J Neurosurg 128:1102–1114 Aoki K, Nakamura H, Suzuki H et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20:66–77 Arita H, Ichimura K (2022) Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas. Brain Tumor Pathol 39:121–129 Arita H, Yamasaki K, Matsushita Y et al (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4:79. https://doi.org/10.1186/s40478-016-0351-2 Bale TA, Jordan JT, Rapalino O et al (2019) Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro Oncol 21:596–605 Bell EH, Zhang P, Shaw EG et al (2020) Comprehensive genomic analysis in NRG oncology/RTOG 9802: A Phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol 38:3407–3417 Berzero G, Di Stefano AL, Ronchi S et al (2021) IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol 23:955–966 Bieńkowski M, Wöhrer A, Moser P et al (2018) Molecular diagnostic testing of diffuse gliomas in the real-life setting: a practical approach. Clin Neuropathol 37:166–177 Brat DJ Ed, Figarella-Branger D, et al. (2021) Gliomas, glioneuronal tumours, and neuronal tumours. In: Board Wcote (editor) Central nervous system tumours 5th edn. International Agency for Research on Cancer pp 15–187 Brito C, Azevedo A, Esteves S et al (2019) Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. BMC Cancer 19:968. https://doi.org/10.1186/s12885-019-6177-0 Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498 Ceccarelli M, Barthel FP, Malta TM et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563 Chan AK, Shi ZF, Li KK et al (2022) Combinations of single-gene biomarkers can precisely stratify 1028 adult gliomas for prognostication. Front Oncol 12:839302. https://doi.org/10.3389/fonc.2022.839302 Di Stefano AL, Enciso-Mora V, Marie Y et al (2013) Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies. Neuro Oncol 15:542–547 Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508 Fleming JL, Pugh SL, Fisher BJ et al (2021) Long-term report of a comprehensive molecular and genomic analysis in NRG oncology/RTOG 0424: a phase II study of radiation and temozolomide in high-risk grade II glioma. JCO Precis Oncol. https://doi.org/10.1200/po.21.00112 Fujimoto K, Arita H, Satomi K et al (2021) TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol 142:323–338 Gorovets D, Kannan K, Shen R et al (2012) IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res 18:2490–2501 Grogan D, Bray DP, Cosgrove M et al (2022) Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review. J Neurooncol 157:187–195 Hasanau T, Pisarev E, Kisil O et al (2022) Detection of TERT promoter mutations as a prognostic biomarker in gliomas: methodology, prospects, and advances. Biomedicines. https://doi.org/10.3390/biomedicines10030728 Hattori N, Hirose Y, Sasaki H et al (2016) World health organization grade II-III astrocytomas consist of genetically distinct tumor lineages. Cancer Sci 107:1159–1164 Heidenreich B, Rachakonda PS, Hosen I et al (2015) TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget 6:10617–10633 Higa N, Akahane T, Yokoyama S et al (2022) Molecular genetic profile of 300 Japanese patients with diffuse gliomas using a glioma-tailored gene panel. Neurol Med Chir (Tokyo) 62:391–399. https://doi.org/10.2176/jns-nmc.2022-0103 Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https://doi.org/10.1186/1471-2288-5-13 Ichimura K (2019) TERT promoter mutation as a diagnostic marker for diffuse gliomas. Neuro Oncol 21:417–418 Izquierdo C, Barritault M, Poncet D et al (2019) Radiological characteristics and natural history of adult IDH-wildtype astrocytomas with TERT promoter mutations. Neurosurgery 85:E448–E456. https://doi.org/10.1093/neuros/nyy513 Jiang C, Kong Z, Zhang Y et al (2020) Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas. Neuroradiology 62:803–813 Killela PJ, Pirozzi PC, Healy P et al (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515–1525 Komori T (2023) Update of the 2021 WHO classification of tumors of the central nervous system: adult diffuse gliomas. Brain Tumor Pathol 40:1–3. https://doi.org/10.1007/s10014-022-00446-1 Kumari K, Dandapath I, Singh J et al (2022) Molecular characterization of IDH wild-type diffuse astrocytomas: the potential of cIMPACT-NOW guidelines. App Immunohistochem Mol Morphol 30:410–417 Kuwahara K, Ohba S, Nakae S et al (2019) Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis. Brain Tumor Pathol 36:135–143 Lasica AB, Jaunmuktane Z, Fersht N et al (2021) Genomic prognosticators and extent of resection in molecularly subtyped World Health Organization grade II and III gliomas-A single-institution, nine-year data. World Neurosurg 151:e217–e233 Li J, Xue Y, Wenger A et al (2019) Individual assignment of adult diffuse gliomas into the EM/PM molecular subtypes using a TaqMan low-density array. Clin Cancer Res 25:7068–7077 Lin AL, Rosenblum M, Mellinghoff IK et al (2020) Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas. Brain Pathol 30:653–660 Ma S, Rudra S, Campian JL et al (2020) Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neurooncol Adv 2:vdaa26. https://doi.org/10.1093/noajnl/vdaa126 Makino Y, Arakawa Y, Yoshioka E et al (2021) Prognostic stratification for IDH-wild-type lower-grade astrocytoma by sanger sequencing and copy-number alteration analysis with MLPA. Sci Rep 11:14408 Mesny E, Barritault M, Izquierdo C et al (2022) Gyriform infiltration as imaging biomarker for molecular glioblastomas. J Neurooncol 157:511–521 Mizoguchi M, Hata N, Kuga D et al (2021) Clinical implications of molecular analysis in diffuse glioma stratification. Brain Tumor Pathol 38:210–217 Mo Z, Xin J, Chai R et al (2022) Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations. Cancer Biol Med 19:1440–1459 Mortensen D, Ulhoi BP, Lukacova S et al (2022) Impact of new molecular criteria on diagnosis and survival of adult glioma patients. IBRO Neurosci Rep 13:299–305 Nakasu S, Nakasu Y (2022) Malignant progression of diffuse low-grade gliomas: a systematic review and meta-analysis on incidence and related factors. Neurol Med Chir (Tokyo) 62:177–185 Nakasu S, Nakasu Y, Tsuji A et al (2023) Incidental diffuse low-grade gliomas: a systematic review and meta-analysis of treatment results with correction of lead-time and length-time biases. Neuro-Oncol Pract 10:113–125. https://doi.org/10.1093/nop/npac073 Park YW, Kim S, Park CJ et al (2022) Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status. Eur Radiol 32:8089–8098. https://doi.org/10.1007/s00330-022-08941-x Pekmezci M, Rice T, Molinaro AM et al (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001–1016 Petersen JK, Boldt HB, Sorensen MD et al (2021) Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics. Neuropathol Appl Neurobiol 47:108–126 Poulen G, Gozé C, Rigau V, Duffau H (2018) Huge heterogeneity in survival in a subset of adult patients with resected, wild-type isocitrate dehydrogenase status, WHO grade II astrocytomas. J Neurosurg 130:1289–1298 Ramos-Fresnedo A, Domingo RA, Perez-Vega C et al (2022) The early infiltrative phase of GBM hypothesis: are molecular glioblastomas histological glioblastomas in the making? A preliminary multicenter study. J Neurooncol 158:497–506 Ramos-Fresnedo A, Pullen MW, Perez-Vega C et al (2022) The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study. J Neurooncol 157:177–185 Reuss DE, Kratz A, Sahm F et al (2015) Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 130:407–417 Ruda R, Bruno F, Ius T et al (2022) IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups. Neuro Oncol 24:809–820 Shibahara I, Sonoda Y, Kanamori M et al (2012) IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol 17:551–561 Stichel D, Ebrahimi A, Reuss D et al (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136:793–803 Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468 Tabouret E, Nguyen AT, Dehais C et al (2016) Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol 132:625–634 Tesileanu CMS, Dirven L, Wijnenga MMJ et al (2020) Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol 22:515–523 Teske N, Karschnia P, Weller J et al (2022) Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma? J Neurooncol 156:317–327 Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. https://doi.org/10.1186/1745-6215-8-16 Wang P, Luo C, Hong PJ et al (2021) The role of surgery in IDH-wild-type lower-grade gliomas: threshold at a high extent of resection should be pursued. Neurosurgery 88:1136–1144 Weller M, Weber RG, Willscher E et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693 Wijnenga MMJ, Dubbink HJ, French PJ et al (2017) Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 134:957–959 Yang P, Cai J, Yan W et al (2016) Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Neuro Oncol 18:1099–1108 Yang Z, Ling F, Ruan S et al (2021) Clinical and Prognostic Implications of 1p/19q, IDH, BRAF, MGMT Promoter, and TERT Promoter Alterations, and Expression of Ki-67 and p53 in Human Gliomas. Cancer Manag Res 13:8755–8765 Zhang Y, Lucas CG, Young JS et al (2022) Prospective genomically guided identification of “early/evolving” and “undersampled” IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro Oncol 24:1749–1762 Zhang ZY, Zhan YB, Zhang FJ et al (2019) Prognostic value of preoperative hematological markers combined with molecular pathology in patients with diffuse gliomas. Aging (Albany NY) 11:6252–6272